3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
cabozantinib
6
Nivolumab
5
Ipilimumab
5
Axitinib
5
Radiosurgery
3
Blood Specimen Collection
3
zimberelimab
2
lenvatinib
2
Ultrasonography
2
Radiotherapy
2
Biopsy
2
tislelizumab
1
polyethylene glycol 3350
1
pazopanib
1
palbociclib
1
orellanine
1
olaparib
1
gallium Ga 68 dotatate
1
fludarabine
1
cyclopropapyrroloindole
1
brodalumab
1
belzutifan
1
atezolizumab
1
anlotinib
1
adagrasib
1
Watchful Waiting
1
Vincristine
1
Therapeutics
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Kidney Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled